Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Subjects: TERAPIA DA REPOSIÇÃO HORMONAL, NEOPLASIAS MAMÁRIAS (ETIOLOGIA;PREVENÇÃO E CONTROLE), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02. Acesso em: 05 out. 2024. , 2015APA
Mattar, A., Goncalves, R., Ellis, M. J., & Hegg, R. (2015). A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-OT2-1-02NLM
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 out. 05 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02Vancouver
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 out. 05 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
